摘要
目的探讨卵巢恶性中胚叶混合瘤的临床特点、治疗及预后因素。方法对我院１９８３年～１９９７年收治的１２例卵巢恶性中胚叶混合瘤的临床资料进行回顾性分析。按ＦＩＧＯ分期（１９８５年），Ⅱ期４例，Ⅲ期６例，Ⅳ期１例，不详１例。组织学分类：同源性８例，异源性４例。１２例均接受肿瘤细胞减灭术。术后辅助化疗１１例，其中３例又追加盆腔放疗。结果全组平均生存２４个月，２，５年生存率分别为３３．３％（４／１２）和８．３％（１／１２）。Ⅱ和Ⅲ期生存２年以上者均为２例，Ⅳ期１例在１年内死亡。同源性８例中，４例生存２年以上，异源性４例均在２年内死亡。综合治疗１１例中，５例在１年内死亡。单纯手术１例在６个月内死亡。结论卵巢恶性中胚叶混合瘤恶性度高，预后差。其组织学类型、分期及治疗方法与预后有关。
Objective To explore the clinical characteristics, treatment and prognostic factors of patients with malignant mixed mesodermal tumors of the ovary (MMMTO). Methods Clinical data of 12 patients with MMMTO between 1983 1997 were reviewed retrospectively. The median age of the patients was 50.7 years. According to FIGO staging system (1985), there were 4 cases in stage Ⅱ, 6 in stage Ⅲ and 1 in stage Ⅳ. Staging was unclear in the remaining case. Heterologous and homologous elements were present in the primary ovarian tumors in 4 and 8 of the 12 patients, respectively. All patients received cytoreductive surgery. Eleven of them received postoperative chemotherapy and 3 of these eleven patients received additional radiotherapy of pelvic field. Results The median survival of this group of 12 patients was 24 months. The 2 and 5 year survival rate was 33.3%(4/12) and 8.33%(1/12), respectivcly. The 2 year survival rate of stage Ⅱ and Ⅲ was 50% and 33.3% respectively. One patent in stage Ⅳ died within 1 year. Four of the 8 patients with homologous histology survived over 2 years while all the 4 cases with heterologous histology died within 2 years. Five of the 11 patients (45.5%) received combination therapy died within 1 year while 1 patient treated with surgery alone died within 6 months. Conclusions The prognosis of MMMTO is rather poor. Surgery combined with chemotherapy and/or radiotherapy seems to be a better choice of approach. The histological tpyes of tumor and stage of the disease are related to prognosis.
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
1998年第6期460-462,共3页
Chinese Journal of Oncology
关键词
卵巢肿瘤
诊断
中胚叶混合瘤
治疗
Ovarian neoplasms/diagnosis Ovarian neoplasms/therapy Mixed mesodermal tumors/diagnosis Mixed mesodermal tumors/therapy
